MiR-221-3p-mediated downregulation of MDM2 reverses the paclitaxel resistance of non-small cell lung cancer in vitro and in vivo

MicroRNAs (miRNAs) are involved in the initiation and development of cancer participate drug resistance. Paclitaxel (PTX) is a first-line chemotherapy for advanced non-small cell lung (NSCLC). The abnormal miRNA expression NSCLC its association with resistance remains largely unknown. study aimed to investigate aberrant miR-221–3p elucidate molecular mechanisms relation PTX increased regulated MDM2/P53 PTX-sensitive strain (A549). Meanwhile, was rarely expressed not interfered by PTX-resistant A549 cells (A549/Taxol). Dual-luciferase reporter assay confirmed that specifically binds MDM2 messenger RNA inhibited expression. P53 showed negative correlation lines. MiR-221–3p down-regulation reduced sensitivity PTX, whereas up-regulation partially reversed A549/Taxol chemosensitivity xenograft models. Quantitative polymerase chain reaction analysis revealed increased, level decreased human tumor tissues. Moreover, Western bolt lowly tissues overexpression. Low might indicate poor T staging. In conclusion, overexpression could regulate MDM2/p53 signaling pathway reverse induce apoptosis vitro vivo.